Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Long-Term Deferred Tax (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $245.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $245.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $245.0 million, a N/A change, with the full-year FY2025 number at $245.0 million, changed N/A from a year prior.
  • Long-Term Deferred Tax was $245.0 million for Q4 2025 at Nuvation Bio.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $245.0 million in Q4 2025 to a low of $245.0 million in Q4 2025.